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Table S1. Search strategy. 
MEDLINE (Ovid) 
1. exp peptic ulcer/  
2. exp peptic ulcer hemorrhage/   
3. (pep$ adj5 ulcer$).tw.  
4. (stomach adj5 ulcer$).tw.     
5. (duoden$ adj5 ulcer$).tw.     
6. (gastr$ adj5 ulcer$).tw.     
7. exp gastritis/     
8. gastritis.tw.     
9. gastropathy.tw.     
10. (bleed$ adj5 ulcer$).tw.     
11. (rebleed$ adj5 ulcer$).tw.     
12. (gastrointestinal adj5 bleed$).tw.     
13. (gastrointestinal adj5 rebleed$).tw.     
14. (gastrointestinal adj5 hemorrhag$).tw.     
15. (gastrointestinal adj5 haemorrhag$).tw.     
16. (ulcer adj5 hemorrhag$).tw.     
17. (ulcer adj5 haemorrhag$).tw.     
18. (mucos$ adj5 injur$).tw.     
19. exp pyloric stenosis/     
20. (pylor$ adj3 stenosis).tw. or (obstruct$).tw.     
21. (gastrointestinal adj3 perforat$).tw.     
22. (gi adj3 perforat$).tw.     
23. (ulcer$ adj3 perforat$).tw.     
24. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
or 22 or 23     
25. exp Anti-inflammatory agents, non-steroidal/     
26. nsaid$.tw.     
27. nonsteroid$ anti-inflammator$.tw.     
28. non-steroid$ anti-inflammator$.tw.     
29. nonsteroid$ antiinflammator$.tw.     
30. non-steroid$ antiinflammator$.tw.     
31. (naproxen or diclofenac or piroxicam or tenoxicam or Ibuprofen or etodolac or nabumetone or flurbiprofen 
or ketoprofen or tiaprofenic or pisoxica or piroxen or sulindac or tolmetin or indomethacin or loxoprofen or 
diflunisal or meloxicam or nimesulide).tw.     
32. 25 or 26 or 27 or 28 or 29 or 30 or 31     
33. exp cyclooxygenase 2 Inhibitors/ 
34. (celecoxib or etoricoxib or lumiracoxib or rofecoxib or valdecoxib or parecoxib).tw. 
35. 33 or 34 
36. randomized controlled trial.pt.     
37. controlled clinical trial.pt. 
38. randomized.ab.    
39. placebo.ab.     
40. drug therapy.fs.    
41. randomly.ab.     
42. trial.ab. 
43. groups.ab.   
44. 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43    
45. exp animals/ not humans.sh.    
46. 44 not 45     
47. 24 and 32 and 35 and 46 
 
 
Table S2. The risk of bias for included studies 
Author, Year (Study name) 
Random 
sequence 
generation 
Allocation  
concealment 
Blinding 
Incomplete 
outcome data 
Selective 
reporting 
Other 
sources of 
bias 
Simon 1999 37 Low  Low Low Low Low Unclear 
Silverstein 2000 (CLASS) 20 Low Low Low Low Unclear Unclear 
Goldstein 2001 22 Low Unclear Low Low Unclear Unclear 
Sikes 2002 36 Unclear Unclear Low Low Low Unclear 
Hunt 2003 33 Unclear Unclear Low Unclear Unclear Unclear 
Lisse 2003 35 Low Unclear Low Low Unclear Unclear 
Kivitz 2004 34 Unclear Unclear Low Low Unclear Unclear 
Schnitzer 2004 (TARGET) 19 Low Low Low Low Unclear Unclear 
Singh 2006 (SUCCESS-I) 5 Low Low Low Low Low Unclear 
Laine 2007 (MEDAL) 18 Low Low Low Low Low Unclear 
Cheung 2010 32 Low Low Low Low Unclear Unclear 
3 
 
 
Table S3. Sensitivity analysis by sample size and risk of bias. 
 
Study removed 
from the primary 
meta-analysis 
Included 
study  
Event/Total RR (95%CI) Heterogeneity 
Sample size      
    Concomitant aspirin use - Yes      
Complicated GI events 1 4 152/18340 0.90 [0.65, 1.23] P = 0.95; I² = 0% 
Clinical GI events 1 4 340/18340 0.77 [0.62, 0.95] P = 0.80; I² = 0% 
Symptomatic ulcer* - - - - - 
Endoscopic Ulcer** 2 0 - - - 
Concomitant aspirin use - No      
Complicated GI events 1 4 162/55767 0.34 [0.13, 0.91] P < 0.001; I² = 82% 
Clinical GI events 1 4 470/55767 0.50 [0.38, 0.65] P = 0.40; I² = 0% 
Symptomatic ulcer* - - - - - 
Endoscopic Ulcer 1 1 38/615 0.20 [0.11, 0.36] Not applicable 
Risk of bias      
    Concomitant aspirin use - Yes      
Complicated GI events 1 4 152/18340 0.90 [0.65, 1.23] P = 0.95; I² = 0% 
Clinical GI events 1 4 340/18340 0.77 [0.62, 0.95] P = 0.80; I² = 0% 
Symptomatic ulcer* - - - - - 
Endoscopic Ulcer*** 2 0 - - - 
Concomitant aspirin use - No      
Complicated GI events 1 4 162/55767 0.34 [0.13, 0.91] P < 0.001; I² = 82% 
Clinical GI events 1 4 470/55767 0.50 [0.38, 0.65] P = 0.40; I² = 0% 
Symptomatic ulcer* - - - - - 
Endoscopic Ulcer*** 2 0 - - - 
RR: relative risk; CI: confidence interval; GI: gastrointestinal.  
Sensitivity analyses according to sample size excluded the studies with <400 participants. Sensitivity analyses according to risk 
of bias excluded the studies with high risk of bias on one or more domain, or with unclear risk of bias on three or more domains. 
* No study was excluded according to our pre-specified sensitivity analysis criteria. 
**The sample size was less than 400 in both of the two studies included in the main analysis, so both were removed. 
***There were three domains at unclear risk of bias according to Cochrane handbook for both of the two studies, so both were 
removed.  
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Figure S1. Meta-analysis evaluating the interaction of low-dose aspirin use and the gastrointestinal benefit of 
coxibs over traditional NSAIDs.   
 
RRR: ratio of relative risk. 
Note: only those studies with subgroup analysis according to concurrent use of low-dose aspirin were combined. 
For each included study, the RRR indicated the ratio of the relative risk in the subgroup of low-dose aspirin 
users and that in the nonusers. An RRR > 1 indicated that the protective effect of coxibs versus traditional 
NSAIDs is lager in non-aspirin users than in low-dose aspirin users 
 
 
